Glabridin inhibits the TGF-β/SMAD2 pathway by upregulating miR-148a, reducing cancer stem cell markers (CD44, EpCAM), and impairing self-renewal, tumor sphere formation, and independent growth. Here, EPCAM is linked to neoplasm.